AEs other than hypoglycaemia (1) SAE (2) Overall AE (3) AE leading to discontinuation
Insulin detemir showed no clear difference in AEs other than hypoglycaemia (1) SAE (2) Overall AE (3) AE leading… compared with NPH insulin (moderate certainty).
1 finding from 1 review
RR 0.88 [0.64, 1.2]
1 study · 8 participants
Moderate
Socioeconomic effects
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diabetes‐related complications (1) Fatal MI (2) Fatal stroke (3) Progression in retinopathy (4) Amputations (5) ESRD
It is very uncertain whether insulin detemir changes diabetes‐related complications (1) Fatal MI (2) Fatal stroke (3)… compared with NPH insulin (very low certainty).
1 finding from 1 review
RR 1.5 [0.68, 3.32]
1 study · 2 participants
Very low
Hypoglycaemic episodes
It is very uncertain whether insulin detemir changes hypoglycaemic episodes (1) Severe hypoglycaemia (2) Serious… compared with NPH insulin (very low certainty).
1 finding from 1 review
RR 0.45 [0.17, 1.2]
1 study · 5 participants
Very low
HbA1c (%)
All‐cause mortality
0.14 [0, 6.98]
8 studies · 2175 participants
Moderate
Peto OR 1.06 [0.62, 1.82]
14 studies · 6173 participants
Low
Diabetes‐related complications (1) Fatal MI (2) Fatal stroke (3) Progression in retinopathy (4) Amputations (5) ESRD
It is very uncertain whether insulin glargine changes diabetes‐related complications (1) Fatal MI (2) Fatal stroke (3)… compared with NPH insulin (very low certainty).
1 finding from 1 review
RR 1.03 [0.6, 1.77]
1 study · 4 participants
Very low
Hypoglycaemic episodes
It is very uncertain whether insulin glargine changes hypoglycaemic episodes(1) Severe hypoglycaemia (2) Serious… compared with NPH insulin (very low certainty).
1 finding from 1 review
Health‐related quality of life
1 finding from 1 review
AEs other than hypoglycaemia (1) SAE (2) Overall AE (3) AE leading to discontinuation
Insulin glargine showed no clear difference in AEs other than hypoglycaemia (1) SAE (2) Overall AE (3) AE leading… compared with NPH insulin (moderate certainty).
1 finding from 1 review
Socioeconomic effects
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (N) Mean hospital stay: 2‐7 days
1 finding from 1 review
Morbidity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than hypoglycaemic episodes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution of diabetic ketoacidosis (h) Mean hospital stay: 3‐5 days
1 finding from 1 review
Patient satisfaction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay
1 finding from 1 review
Hypoglycaemic episodes
Subcutaneous insulin lispro showed no clear difference in hypoglycaemic episodes (N) Mean hospital stay: 2‐7 days compared with intravenous regular insulin (low certainty).
1 finding from 1 review
Length of hospital stay
2 findings from 1 review
Adverse events other than hypoglycaemic episodes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found